## Clinical Context A 58-year-old male smoker with haemoptysis and a 3 cm peripheral solitary pulmonary nodule (SPN) with no mediastinal lymphadenopathy or distant metastases on CT, and inconclusive bronchoscopy + TTNAC, represents a high-probability malignancy scenario. The question asks for the **best next step** when non-invasive and minimally invasive sampling have both failed. ## Rationale for Diagnostic VATS with Wedge Resection **Key Point:** When cytological/histological sampling of a peripheral lung nodule is inconclusive after standard attempts (bronchoscopy + TTNAC), current guidelines (NCCN, BTS, ACCP) recommend **surgical resection** — specifically VATS wedge resection — as the next step. This approach simultaneously achieves: 1. **Definitive tissue diagnosis** (frozen section intraoperatively) 2. **Curative resection** if malignancy is confirmed (converted to lobectomy if needed) 3. **Avoidance of further diagnostic delay** in a high-risk patient **High-Yield:** For a peripheral nodule ≥2 cm in a high-risk smoker with inconclusive prior sampling, VATS wedge resection is both diagnostic AND potentially therapeutic in a single procedure. This is the standard of care per ACCP Evidence-Based Clinical Practice Guidelines (Chest 2013) and NCCN NSCLC guidelines. ## Why Not the Other Options? - **Option A (Repeat CT-guided TTNAC):** TTNAC has already been performed and was inconclusive. Repeating it carries additional risk (pneumothorax ~15–25%) with a significant chance of another non-diagnostic result, especially for peripheral nodules with necrotic or heterogeneous tissue. Guidelines do not recommend routine repeat sampling when surgical resection is feasible. - **Option C (Empirical chemotherapy):** Absolutely contraindicated without tissue diagnosis. "Tissue before treatment" is a cardinal oncology principle. Starting chemotherapy without histological confirmation violates standard of care. - **Option D (PET-CT followed by staging):** PET-CT is valuable for staging **after** a tissue diagnosis is established, or when the pre-test probability of malignancy is intermediate and non-invasive characterisation may change management. In this case, the patient already has a high-probability malignant nodule with no CT evidence of metastases, and two sampling attempts have failed. PET-CT would add delay without providing the tissue diagnosis needed to guide treatment. Moreover, if PET-CT shows no metastases, VATS would still be required — making it an unnecessary intermediate step. ## Management Algorithm for Inconclusive Sampling of High-Risk SPN ``` Peripheral SPN + inconclusive bronchoscopy + inconclusive TTNAC ↓ High clinical suspicion (smoker, ≥2 cm, spiculated) ↓ VATS Wedge Resection (diagnostic + potentially curative) ↓ Frozen section: Malignant? → Convert to lobectomy + lymph node dissection Frozen section: Benign? → Wedge resection sufficient; close ``` **Clinical Pearl:** The principle of "one-stop diagnosis and treatment" via VATS is preferred over repeated failed sampling or staging investigations that delay definitive management in a surgically fit patient with a resectable lesion. [cite: ACCP Evidence-Based Clinical Practice Guidelines, Chest 2013; NCCN NSCLC Guidelines v2024; Harrison's Principles of Internal Medicine 21e, Ch 89]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.